Professional Summary »
Specializing In »
Practice Locations »
Patient Ratings »
Referring Physicians »
Professional Summary
Professional Education
- Residency: Albert Einstein College of Medicine (2002) NY
- Medical Education: Medizinische Hochschule Hannover (1996) Germany
- Fellowship: Memorial Sloan-Kettering Cancer Center (2004) NY
- Board Certification: American Board of Internal Medicine, Hematology (2005)
- Fellowship: Stanford University Medical Center (2005) CA
Honors & Awards
- Fellowship Award, Lymphoma Research Foundation (2004)
- Methods in Clinical Cancer Research Scholar, ASCO/AACR (2005)
- Research grant, Hope Street Kids Foundation (2006)
- Translational Research Award, Doris Duke Foundation (2004)
- Translational Research Award, Stanford Department of Medicine (2011)
- Young Investigator Award, ASCO (2008)
Administrative Appointments
- Cancer Center Program Lead, Hematology, Stanford (2019 - Present)
- Co-Director, Stanford Amyloid Center (2010 - Present)
- Medical Director, Stanford Adolescent and Young Adult Program (2015 - Present)
- Member Leukemia Committee, Southwest Oncology Group (2011 - Present)
- Unit Based Medical Director Inpatient Hematology, Stanford (2019 - 2021)
Publications
-
A SITE-DIRECTED MUTAGENESIS STUDY TO IDENTIFY AMINO-ACID-RESIDUES INVOLVED IN THE CATALYTIC FUNCTION OF THE RESTRICTION ENDONUCLEASE ECORV
SELENT, U., RUTER, T., Kohler, E., Liedtke, M., THIELKING, V., Alves, J., … Pingoud, A. (1992). A SITE-DIRECTED MUTAGENESIS STUDY TO IDENTIFY AMINO-ACID-RESIDUES INVOLVED IN THE CATALYTIC FUNCTION OF THE RESTRICTION ENDONUCLEASE ECORV. BIOCHEMISTRY, 31(20), 4808–4815. -
Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population
Liedtke, M., Hamlin, P. A., Moskowitz, C. H., & Zelenetz, A. D. (2006). Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population. ANNALS OF ONCOLOGY, 17(6), 909–913. -
Reversible high-output cardiac failure, an unusual marker of disease status in multiple myeloma
Kohrt, H., Logan, A., Temmins, C., Witteles, R., Liedtke, M., & Medeiros, B. (2008). Reversible high-output cardiac failure, an unusual marker of disease status in multiple myeloma. LEUKEMIA & LYMPHOMA, 49(3), 581–85. -
Therapeutic targeting of MLL
Liedtke, M., & Cleary, M. L. (2009). Therapeutic targeting of MLL. BLOOD, 113(24), 6061–68. -
Self-association mediated by the Ras association 1 domain of AF6 activates the oncogenic potential of MLL-AF6
Liedtke, M., Ayton, P. M., Somervaille, T. C. P., Smith, K. S., & Cleary, M. L. (2010). Self-association mediated by the Ras association 1 domain of AF6 activates the oncogenic potential of MLL-AF6. BLOOD, 116(1), 63–70. -
Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: A single-center experience
Kohrt, H. E., Patel, S., Ho, M., Owen, T., Pollyea, D. A., Majeti, R., … Medeiros, B. C. (2010). Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: A single-center experience. AMERICAN JOURNAL OF HEMATOLOGY, 85(11), 877–81. -
Plasma cell leukemia: concepts and management.
Liedtke, M., & Medeiros, B. C. (2010). Plasma cell leukemia: concepts and management. Expert Review of Hematology, 3(5), 543–49. -
Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia
Liedtke, M., Twist, C. J., Medeiros, B. C., Gotlib, J. R., Berube, C., Bieber, M. M., … Coutre, S. E. (2012). Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 97(1), 30–37. -
Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia
Pollyea, D. A., Kohrt, H. E., Gallegos, L., Figueroa, M. E., Abdel-Wahab, O., Zhang, B., … Medeiros, B. C. (2012). Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia. LEUKEMIA, 26(5), 893–901. -
Heart transplantation and cardiac amyloidosis: Approach to screening and novel management strategies
Varr, B. C., Liedtke, M., Arai, S., Lafayette, R. A., Schrier, S. L., & Witteles, R. M. (2012). Heart transplantation and cardiac amyloidosis: Approach to screening and novel management strategies. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 31(3), 325–31. -
The Transcription Factor Encyclopedia
Yusuf, D., Butland, S. L., Swanson, M. I., Bolotin, E., Ticoll, A., Cheung, W. A., … Wasserman, W. W. (2012). The Transcription Factor Encyclopedia. GENOME BIOLOGY, 13(3). -
More Than a Frog in the Throat A Case Series and Review of Localized Laryngeal Amyloidosis
Stevenson, R., Witteles, R., Damrose, E., Arai, S., Lafayette, R. A., Schrier, S., … Liedtke, M. (2012). More Than a Frog in the Throat A Case Series and Review of Localized Laryngeal Amyloidosis. ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 138(5), 509–11. -
Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed acute lymphoblastic leukemia
Sun, D., Elson, P., Liedtke, M., Medeiros, B. C., Earl, M., Alizadeh, A., … Advani, A. S. (2012). Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed acute lymphoblastic leukemia. AMERICAN JOURNAL OF HEMATOLOGY, 87(10), 957–60. -
Hemophagocytic lymphohistiocytosis in pregnancy: A case report and review of treatment options.
Dunn, T., Cho, M., Medeiros, B., Logan, A., Ungewickell, A., & Liedtke, M. (2012). Hemophagocytic lymphohistiocytosis in pregnancy: A case report and review of treatment options. Hematology (Amsterdam, Netherlands). -
Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia.
Pollyea, D. A., Zehnder, J., Coutre, S., Gotlib, J. R., Gallegos, L., Abdel-Wahab, O., … Medeiros, B. C. (2013). Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia. Haematologica, 98(4), 591–96. -
Multiple Myeloma, Version 1.2013 Featured Updates to the NCCN Guidelines
Anderson, K. C., Alsina, M., Bensinger, W., Biermann, J. S., Cohen, A. D., Devine, S., … Kumar, R. (2013). Multiple Myeloma, Version 1.2013 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 11(1), 11–17. -
A single-center experience of the nationwide daunorubicin shortage: substitution with doxorubicin in adult acute lymphoblastic leukemia.
Patel, S., Liedtke, M., Ngo, D., & Medeiros, B. C. (2013). A single-center experience of the nationwide daunorubicin shortage: substitution with doxorubicin in adult acute lymphoblastic leukemia. Leukemia & Lymphoma, 54(10), 2231–35. -
The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis
Dinner, S., Witteles, W., Witteles, R., Lam, A., Arai, S., Lafayette, R., … Liedtke, M. (2013). The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis. BRITISH JOURNAL OF HAEMATOLOGY, 161(3), 367–72. -
Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement.
Dinner, S., Witteles, W., Afghahi, A., Witteles, R., Arai, S., Lafayette, R., … Liedtke, M. (2013). Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement. Haematologica, 98(10), 1593–99. -
AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin
Penchala, S. C., Connelly, S., Wang, Y., Park, M. S., Zhao, L., Baranczak, A., … Alhamadsheh, M. M. (2013). AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 110(24), 9992–97. -
Regulation of Bcr-Abl-induced SAP kinase activity and transformation by the SHPTP1 protein tyrosine phosphatase
Liedtke, M., Pandey, P., Kumar, S., KHARBANDA, S., & Kufe, D. (1998). Regulation of Bcr-Abl-induced SAP kinase activity and transformation by the SHPTP1 protein tyrosine phosphatase. ONCOGENE, 17(15), 1889–1892. -
Amrubicin, a Novel Investigational Anthracycline, in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase 1 Dose-Escalation Study
Dinner, S. N., Dunn, T. J., Medeiros, B. C., Coutre, S. E., Berube, C., Gotlib, J., & Liedtke, M. (2012). Amrubicin, a Novel Investigational Anthracycline, in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase 1 Dose-Escalation Study. BLOOD, 120(21). -
Cardiac Amyloidosis: Screening Criteria for Heart Transplantation and New Strategies for Post-Transplant Therapy
Varr, B. C., Liedtke, M., Arai, S., Lafayette, R. A., Schrier, S. L., & Witteles, R. M. (2011). Cardiac Amyloidosis: Screening Criteria for Heart Transplantation and New Strategies for Post-Transplant Therapy. JOURNAL OF CARDIAC FAILURE, 17(8), S45–S46. -
Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis
Varr, B. C., Zarafshar, S., Coakley, T., Liedtke, M., Lafayette, R. A., Arai, S., … Witteles, R. M. (2014). Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis. HEART RHYTHM, 11(1), 158–62. -
Indolent T-lymphoblastic Proliferation With Disseminated Multinodal Involvement and Partial CD33 Expression.
Ohgami, R. S., Sendamarai, A. K., Atwater, S. K., Liedtke, M., Fleming, M. D., Natkunam, Y., & Warnke, R. A. (2014). Indolent T-lymphoblastic Proliferation With Disseminated Multinodal Involvement and Partial CD33 Expression. American Journal of Surgical Pathology, 38(9), 1298–1304. -
Effects of serum and plasma matrices on multiplex immunoassays.
Rosenberg-Hasson, Y., Hansmann, L., Liedtke, M., Herschmann, I., & Maecker, H. T. (2014). Effects of serum and plasma matrices on multiplex immunoassays. Immunologic Research, 58(2-3), 224–33. -
Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia
Dinner, S., Lee, D., & Liedtke, M. (2014). Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia. LEUKEMIA & LYMPHOMA, 55(8), 1715–24. -
Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia
Liedtke, M., Dunn, T., Dinner, S., Coutre, S. E., Berubea, C., Gotlib, J., … Medeiros, B. (2014). Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia. LEUKEMIA RESEARCH, 38(12), 1441–45. -
Outcomes after heart transplantation for amyloid cardiomyopathy in the modern era.
Davis, M. K., Kale, P., Liedtke, M., Schrier, S., Arai, S., Wheeler, M., … Witteles, R. M. (2015). Outcomes after heart transplantation for amyloid cardiomyopathy in the modern era. American Journal of Transplantation , 15(3), 650–58. -
Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome.
Narayan, R., Garcia, J. S., Percival, M.-E. M., Berube, C., Coutre, S., Gotlib, J., … Medeiros, B. C. (2016). Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome. Leukemia & Lymphoma, 57(3), 609–15. -
Mass Cytometry Analysis Shows That a Novel Memory Phenotype B Cell Is Expanded in Multiple Myeloma
Hansmann, L., Blum, L., Ju, C.-H., Liedtke, M., Robinson, W. H., & Davis, M. M. (2015). Mass Cytometry Analysis Shows That a Novel Memory Phenotype B Cell Is Expanded in Multiple Myeloma. CANCER IMMUNOLOGY RESEARCH, 3(6), 650–60. -
CD93 Marks a Non-Quiescent Human Leukemia Stem Cell Population and Is Required for Development of MLL-Rearranged Acute Myeloid Leukemia.
Iwasaki, M., Liedtke, M., Gentles, A. J., & Cleary, M. L. (2015). CD93 Marks a Non-Quiescent Human Leukemia Stem Cell Population and Is Required for Development of MLL-Rearranged Acute Myeloid Leukemia. Cell Stem Cell, 17(4), 412–21. -
Multiple Myeloma, Version 2.2016
Anderson, K. C., Alsina, M., Atanackovic, D., Biermann, J. S., Chandler, J. C., Costello, C., … Kumar, R. (2015). Multiple Myeloma, Version 2.2016. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 13(11), 1398–1435. -
A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myeloma.
Dunn, T. J., Dinner, S., Price, E., Coutré, S. E., Gotlib, J., Hao, Y., … Liedtke, M. (2016). A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myeloma. British Journal of Haematology, 173(2), 253–59. -
First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction.
Gertz, M. A., Landau, H., Comenzo, R. L., Seldin, D., Weiss, B., Zonder, J., … Liedtke, M. (2016). First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction. Journal of Clinical Oncology , 34(10), 1097–1103. -
Recurrent Subepidermal Blistering Dermatosis Heralding Disease Relapse in IgA Kappa Multiple Myeloma: Report of a Case and a Review of the Literature.
Leatham, H. W., Novoa, R., Liedtke, M., & Kwong, B. Y. (2016). Recurrent Subepidermal Blistering Dermatosis Heralding Disease Relapse in IgA Kappa Multiple Myeloma: Report of a Case and a Review of the Literature. Clinical Lymphoma, Myeloma & Leukemia, 16(1), e1–5. -
Identification of Doxorubicin as an Inhibitor of the IRE1a-XBP1 Axis of the Unfolded Protein Response.
Jiang, D., Lynch, C., Medeiros, B. C., Liedtke, M., Bam, R., Tam, A. B., … Koong, A. C. (2016). Identification of Doxorubicin as an Inhibitor of the IRE1a-XBP1 Axis of the Unfolded Protein Response. Scientific Reports, 6, 33353-? -
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.
Kantarjian, H. M., DeAngelo, D. J., Stelljes, M., Martinelli, G., Liedtke, M., Stock, W., … Advani, A. S. (2016). Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. New England Journal of Medicine, 375(8), 740–53. -
Multiple Myeloma, Version 3.2016 Featured Updates to the NCCN Guidelines
Anderson, K. C., Alsina, M., Atanackovic, D., Biermann, J. S., Chandler, J. C., Costello, C., … Kumar, R. (2016). Multiple Myeloma, Version 3.2016 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 14(4), 389–400. -
Multiple Myeloma, Version 3.2017 Clinical Practice Guidelines in Oncology
Kumar, S. K., Callander, N. S., Alsina, M., Atanackovic, D., Biermann, J. S., Chandler, J. C., … Kumar, R. (2017). Multiple Myeloma, Version 3.2017 Clinical Practice Guidelines in Oncology. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 15(2), 230-? -
Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial.
DeAngelo, D. J., George, T. I., Linder, A., Langford, C., Perkins, C., Ma, J., … Gotlib, J. (2017). Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial. Leukemia. -
Functional Cardiac Recovery and Hematologic Response to Chemotherapy in Patients With Light-Chain Amyloidosis (from the Stanford University Amyloidosis Registry).
Tuzovic, M., Kobayashi, Y., Wheeler, M., Barrett, C., Liedtke, M., Lafayette, R., … Witteles, R. (2017). Functional Cardiac Recovery and Hematologic Response to Chemotherapy in Patients With Light-Chain Amyloidosis (from the Stanford University Amyloidosis Registry). The American Journal of Cardiology, 120(8), 1381–86. -
Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML).
Advani, A. S., Li, H., Michaelis, L. C., Medeiros, B. C., Liedtke, M., List, A. F., … Appelbaum, F. R. (2018). Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML). Leukemia Research, 67, 17–20. -
NEOD001 DEMONSTRATES CARDIAC BIOMARKER RESPONSES IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS: RESULTS FROM THE PHASE 1/2 STUDY
Liedtke, M., Comenzo, R., Landau, H., Sanchorawala, V., Weiss, B., Zonder, J., … Gertz, M. (2017). NEOD001 DEMONSTRATES CARDIAC BIOMARKER RESPONSES IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS: RESULTS FROM THE PHASE 1/2 STUDY. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 69(11), 825. -
NEOD001 demonstrates organ biomarker responses in patients with light chain amyloidosis and persistent organ dysfunction independently of previous haematological response
Liedtke, M. M., Comenzo, R. L., Landau, H., Sanchorawala, V., Weiss, B. M., Zonder, J. A., … Gertz, M. A. (2017). NEOD001 demonstrates organ biomarker responses in patients with light chain amyloidosis and persistent organ dysfunction independently of previous haematological response. EUROPEAN JOURNAL OF HEART FAILURE, 19, 441. -
A Phase I Dose-Escalation Study of Carfilzomib in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis
Cohen, A. D., Scott, E. C., Liedtke, M., Kaufman, J. L., Landau, H., Vesole, D. H., … Durie, B. G. M. (2014). A Phase I Dose-Escalation Study of Carfilzomib in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis. BLOOD, 124(21). -
Recommendations from the Amyloidosis Research Consortium Educational Roundtable at the American College of Cardiology Annual Meeting, 1 April 2016
Maurer, M., Lousada, I., Hanna, M., Ruberg, F., Mohty, D., Dispenzieri, A., … Grogan, M. (2017). Recommendations from the Amyloidosis Research Consortium Educational Roundtable at the American College of Cardiology Annual Meeting, 1 April 2016. AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 24, 165–66. -
Report of the Relapsed/Refractory Cohort of SWOG S0919: A Phase 2 Study of Idarubicin and Cytarabine in Combination with Pravastatin for Acute Myelogenous Leukemia
Advani, A. S., Li, H., Michaelis, L. C., Medeiros, B. C., Liedtke, M., List, A. F., … Appelbaum, F. R. (2015). Report of the Relapsed/Refractory Cohort of SWOG S0919: A Phase 2 Study of Idarubicin and Cytarabine in Combination with Pravastatin for Acute Myelogenous Leukemia. BLOOD, 126(23). -
The VITAL study: A randomized, double-blind, placebo-controlled, global, phase III study of NEOD001 in patients with AL amyloidosis and cardiac dysfunction.
Liedtke, M., Merlini, G., Landau, H. J., Comenzo, R., Seldin, D. C., Weiss, B. M., … Gertz, M. A. (2015). The VITAL study: A randomized, double-blind, placebo-controlled, global, phase III study of NEOD001 in patients with AL amyloidosis and cardiac dysfunction. JOURNAL OF CLINICAL ONCOLOGY, 33(15). -
NEOD001 demonstrates cardiac biomarker responses in patients with light chain amyloidosis and persistent organ dysfunction: results from the expansion phase of a phase 1/2 study
Liedtke, M., Comenzo, R. L., Landau, H., Sanchorawala, V., Weiss, B. M., Zonder, J. A., … Gertz, M. A. (2016). NEOD001 demonstrates cardiac biomarker responses in patients with light chain amyloidosis and persistent organ dysfunction: results from the expansion phase of a phase 1/2 study. EUROPEAN HEART JOURNAL, 37, 220. -
Clonal Expansion and Interrelatedness of Distinct B-Lineage Compartments in Multiple Myeloma Bone Marrow
Hansmann, L., Han, A., Penter, L., Liedtke, M., & Davis, M. M. (2017). Clonal Expansion and Interrelatedness of Distinct B-Lineage Compartments in Multiple Myeloma Bone Marrow. CANCER IMMUNOLOGY RESEARCH, 5(9), 744–54. -
NCCN Guidelines (R) Insights Multiple Myeloma, Version 3.2018 Featured Updates to the NCCN Guidelines
Kumar, S. K., Callander, N. S., Alsina, M., Atanackovic, D., Biermann, J. S., Castillo, J., … Shead, D. A. (2018). NCCN Guidelines (R) Insights Multiple Myeloma, Version 3.2018 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 16(1), 11–20. -
Clinical implications of gastrointestinal symptoms in systemic amyloidosis
Yen, T., Chen, F. W., Witteles, R. M., Liedtke, M., & Nguyen, L. A. (2018). Clinical implications of gastrointestinal symptoms in systemic amyloidosis. NEUROGASTROENTEROLOGY AND MOTILITY, 30(4), e13229. -
NEOD001 demonstrates organ biomarker responses in patients with light chain amyloidosis and persistent organ dysfunction independently of previous hematologic response
Liedtke, M., Comenzo, R. L., Landau, H., Sanchorawala, V., Weiss, B. M., Zonder, J. A., … Gertz, M. A. (2017). NEOD001 demonstrates organ biomarker responses in patients with light chain amyloidosis and persistent organ dysfunction independently of previous hematologic response. ONCOLOGY RESEARCH AND TREATMENT, 40, 34–35. -
NEOD001 DEMONSTRATES DURABLE PERIPHERAL NEUROPATHY RESPONSES IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS AND PERSISTENT ORGAN DYSFUNCTION: RESULTS FROM A PHASE 1/2 STUDY
Gertz, M., Comenzo, R. L., Landau, H., Sanchorawala, Weiss, B. M., Zonder, J. A., … Liedtke, M. (2017). NEOD001 DEMONSTRATES DURABLE PERIPHERAL NEUROPATHY RESPONSES IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS AND PERSISTENT ORGAN DYSFUNCTION: RESULTS FROM A PHASE 1/2 STUDY. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 22(3), 289–90. -
Efficacy and Safety Analysis by Age Cohort of Inotuzumab Ozogamicin in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia Enrolled in INO-VATE
Jabbour, E. J., DeAngelo, D. J., Stelljes, M., Stock, W., Liedtke, M., Gokbuget, N., … Kantarjian, H. M. (2018). Efficacy and Safety Analysis by Age Cohort of Inotuzumab Ozogamicin in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia Enrolled in INO-VATE. CANCER, 124(8), 1722–32. -
Novel therapeutic approaches for AL amyloid
Liedtke, M. (2017). Novel therapeutic approaches for AL amyloid. ONCOLOGY RESEARCH AND TREATMENT, 40, 194. -
Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study
DeAngelo, D. J., Stock, W., Stein, A. S., Shustov, A., Liedtke, M., Schiffer, C. A., … Advani, A. S. (2017). Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study. BLOOD ADVANCES, 1(15), 1167–80. -
Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis
Kaufman, G. P., Schrier, S. L., Lafayette, R. A., Arai, S., Witteles, R. M., & Liedtke, M. (2017). Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis. BLOOD, 130(7), 900–902. -
Prognostic impact of incomplete hematologic count recovery and minimal residual disease on outcome in adult acute lymphoblastic leukemia at the time of second complete response
Saygin, C., Papadantonakis, N., Cassaday, R. D., Liedtke, M., Fischer, K., Dunn, T., … Advani, A. S. (2018). Prognostic impact of incomplete hematologic count recovery and minimal residual disease on outcome in adult acute lymphoblastic leukemia at the time of second complete response. LEUKEMIA & LYMPHOMA, 59(2), 363–71. -
A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma.
Dinner, S., Dunn, T. J., Price, E., Coutré, S. E., Gotlib, J., Berube, C., … Liedtke, M. (2018). A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma. International Journal of Hematology. -
Effect of Fitbit and iPad Wearable Technology in Health-Related Quality of Life in Adolescent and Young Adult Cancer Patients.
Yurkiewicz, I. R., Simon, P., Liedtke, M., Dahl, G., & Dunn, T. (2018). Effect of Fitbit and iPad Wearable Technology in Health-Related Quality of Life in Adolescent and Young Adult Cancer Patients. Journal of Adolescent and Young Adult Oncology. -
Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma
Richardson, P. G., Hofmeister, C. C., Rosenbaum, C. A., Htut, M., Vesole, D. H., Berdeja, J. G., … Baz, R. (2018). Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma. BRITISH JOURNAL OF HAEMATOLOGY, 182(2), 231–44. -
Inotuzumab ozogamicin: a CD22 mAb-drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia
Yurkiewicz, I. R., Muffly, L., & Liedtke, M. (2018). Inotuzumab ozogamicin: a CD22 mAb-drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia. DRUG DESIGN DEVELOPMENT AND THERAPY, 12, 2293–2300. -
Epidemiology and Clinical Implications of Gastrointestinal Symptoms in Systemic Amyloidosis
Yen, T., Chen, F., Witteles, R., Liedtke, M., & Nguyen, L. A. (2017). Epidemiology and Clinical Implications of Gastrointestinal Symptoms in Systemic Amyloidosis. AMERICAN JOURNAL OF GASTROENTEROLOGY. NATURE PUBLISHING GROUP. -
Antibody-based therapies in patients with acute lymphoblastic leukemia.
Dinner, S., & Liedtke, M. (2018). Antibody-based therapies in patients with acute lymphoblastic leukemia. Hematology. American Society of Hematology. Education Program, 2018(1), 9–15. -
Daratumumab vs. pomalidomide for the treatment of relapsed/refractory multiple myeloma: a cost-effectiveness analysis.
Gong, C. L., Studdert, A. L., & Liedtke, M. (2018). Daratumumab vs. pomalidomide for the treatment of relapsed/refractory multiple myeloma: a cost-effectiveness analysis. American Journal of Hematology. -
Grading cardiac response in AL amyloidosis: implications for relapse and survival.
Eckhert, E., Witteles, R., Kaufman, G., Lafayette, R., Arai, S., Schrier, S., … Liedtke, M. (2018). Grading cardiac response in AL amyloidosis: implications for relapse and survival. British Journal of Haematology. -
Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin.
Jabbour, E., Advani, A. S., Stelljes, M., Stock, W., Liedtke, M., Gokbuget, N., … Kantarjian, H. M. (2019). Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin. American Journal of Hematology. -
A Phase II Study of Dasatinib and Dexamethasone As Primary Therapy Followed By Transplantation for Adults with Newly Diagnosed Ph/BCR-ABL1-Positive Acute Lymphoblastic Leukemia (Ph plus ALL): Final Results of Alliance/CALGB Study 10701
Wieduwilt, M. J., Yin, J., Wetzler, M., Uy, G. L., Powell, B. L., Kolitz, J. E., … Larson, R. A. (2018). A Phase II Study of Dasatinib and Dexamethasone As Primary Therapy Followed By Transplantation for Adults with Newly Diagnosed Ph/BCR-ABL1-Positive Acute Lymphoblastic Leukemia (Ph plus ALL): Final Results of Alliance/CALGB Study 10701. BLOOD, 132. -
Single-Cell Mutational Profiling of Clonal Evolution in De Novo AML during Therapy and Relapse
Aleshin, A., Durruthy-Durruthy, R., Corces, M. R., Stafford, M., Liedtke, M., Medeiros, B. C., … Majeti, R. (2018). Single-Cell Mutational Profiling of Clonal Evolution in De Novo AML during Therapy and Relapse. BLOOD, 132. -
Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.
Gandhi, U. H., Cornell, R. F., Lakshman, A., Gahvari, Z. J., McGehee, E., Jagosky, M. H., … Costa, L. J. (2019). Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. -
Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study.
Kantarjian, H. M., DeAngelo, D. J., Stelljes, M., Liedtke, M., Stock, W., Gokbuget, N., … Advani, A. S. (2019). Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Cancer. -
Contemporary Outcomes in Patients with Cardiac Amyloidosis Undergoing Heart Transplantation
Alexander, K., Barrett, C., Dobos, K., Cheng, P., Liao, R., Wheeler, M., … Witteles, R. (2019). Contemporary Outcomes in Patients with Cardiac Amyloidosis Undergoing Heart Transplantation. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 38(4), S215. -
Therapy-related myeloid neoplasms after treatment for plasma-cell disorders.
Chung, A., & Liedtke, M. (2019). Therapy-related myeloid neoplasms after treatment for plasma-cell disorders. Best Practice & Research. Clinical Haematology, 32(1), 54–64. -
Therapy-related myeloid neoplasms after treatment for plasma-cell disorders
Chung, A., & Liedtke, M. (2019). Therapy-related myeloid neoplasms after treatment for plasma-cell disorders. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 32(1), 54–64. -
A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403
Stock, W., Luger, S. M., Advani, A. S., Yin, J., Harvey, R. C., Mullighan, C. G., … Larson, R. A. (2019). A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. BLOOD, 133(14), 1548–59. -
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
Raje, N., Berdeja, J., Lin, Y., Siegel, D., Jagannath, S., Madduri, D., … Kochenderfer, J. N. (2019). Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. NEW ENGLAND JOURNAL OF MEDICINE, 380(18), 1726–37. -
B-cell maturation antigen directed monoclonal antibody therapies for multiple myeloma
Eckhert, E., Hewitt, R., & Liedtke, M. (2019). B-cell maturation antigen directed monoclonal antibody therapies for multiple myeloma. IMMUNOTHERAPY, 11(9), 801–11. -
Effect of Fitbit and iPad Wearable Technology in Health-Related Quality of Life in Adolescent and Young Adult Cancer Patients
Yurkiewicz, I. R., Simon, P., Liedtke, M., Dahl, G., & Dunn, T. (2018). Effect of Fitbit and iPad Wearable Technology in Health-Related Quality of Life in Adolescent and Young Adult Cancer Patients. JOURNAL OF ADOLESCENT AND YOUNG ADULT ONCOLOGY, 7(5), 579–83. -
Grading cardiac response in AL amyloidosis: implications for relapse and survival
Eckhert, E., Witteles, R., Kaufman, G., Lafayette, R., Arai, S., Schrier, S., … Liedtke, M. (2019). Grading cardiac response in AL amyloidosis: implications for relapse and survival. BRITISH JOURNAL OF HAEMATOLOGY, 186(1), 144–46. -
Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study
Kantarjian, H. M., DeAngelo, D. J., Stelljes, M., Liedtke, M., Stock, W., Goekbuget, N., … Advani, A. S. (2019). Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. CANCER, 125(14), 2474–87. -
Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy
Gandhi, U. H., Cornell, R. F., Lakshman, A., Gahvari, Z. J., McGehee, E., Jagosky, M. H., … Costa, L. J. (2019). Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. LEUKEMIA, 33(9), 2266–75. -
Outcome of relapsed or refractory acute lymphoblastic leukemia patients with extramedullary disease or lymphoblastic lymphoma receiving inotuzumab ozogamicin or standard care in the INO-VATE trial
Marks, D. I., DeAngelo, D. J., Stelljes, M., Liedtke, M., Stock, W., Gokbuget, N., … Kantarjian, H. (2019). Outcome of relapsed or refractory acute lymphoblastic leukemia patients with extramedullary disease or lymphoblastic lymphoma receiving inotuzumab ozogamicin or standard care in the INO-VATE trial. BONE MARROW TRANSPLANTATION, 54, 149–51. -
A Changing Landscape of Mortality for Systemic Light Chain Amyloidosis.
Barrett, C. D., Dobos, K., Liedtke, M., Tuzovic, M., Haddad, F., Kobayashi, Y., … Witteles, R. M. (2019). A Changing Landscape of Mortality for Systemic Light Chain Amyloidosis. JACC. Heart Failure. -
Single-cell mutational profiling of paired AML samples at diagnosis, remission and relapse: Implications for therapeutic resistance and MRD detection
Aleshin, A., Durruthy-Durruthy, R., Corces, R., Liedtke, M., Eastburn, D., & Majeti, R. (2019). Single-cell mutational profiling of paired AML samples at diagnosis, remission and relapse: Implications for therapeutic resistance and MRD detection. CANCER RESEARCH, 79(13). -
Multiple Myeloma, Version 1.2020 Featured Updates to the NCCN Guidelines
Kumar, S. K., Callender, N. S., Hillengass, J., Liedtke, M., Baljevic, M., Campagnaro, E., … Kumar, R. (2019). Multiple Myeloma, Version 1.2020 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 17(10), 1155–65. -
Real world vs. clinical trial outcomes of triple class refractory penta-exposed multiple myeloma (MM)
Cornell, R., Parameswaran, H., Tang, S., Barnstead, A., Biran, N., Callander, N., … Costa, L. (2019). Real world vs. clinical trial outcomes of triple class refractory penta-exposed multiple myeloma (MM). CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 19(10), E115–E116. -
Single-cell multiomic analysis identifies regulatory programs in mixed-phenotype acute leukemia.
Granja, J. M., Klemm, S., McGinnis, L. M., Kathiria, A. S., Mezger, A., Corces, M. R., … Greenleaf, W. J. (2019). Single-cell multiomic analysis identifies regulatory programs in mixed-phenotype acute leukemia. Nature Biotechnology. -
Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial.
Jabbour, E., Gokbuget, N., Advani, A., Stelljes, M., Stock, W., Liedtke, M., … Kantarjian, H. (2019). Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial. Leukemia Research, 88, 106283. -
Cutaneous plasmablastic plasmacytoma.
Chung, A., & Liedtke, M. (2019). Cutaneous plasmablastic plasmacytoma. Blood, 134(23), 2116. -
Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes.
Saygin, C., Kishtagari, A., Cassaday, R. D., Reizine, N., Yurkiewicz, I., Liedtke, M., … Advani, A. S. (2019). Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes. Blood Advances, 3(24), 4228–37. -
Organ responses with daratumumab therapy in previously treated AL amyloidosis.
Chung, A., Kaufman, G. P., Sidana, S., Eckhert, E., Schrier, S. L., Lafayette, R. A., … Liedtke, M. (2020). Organ responses with daratumumab therapy in previously treated AL amyloidosis. Blood Advances, 4(3), 458–66. -
Gene Signatures to Distinguish Amyloid Cardiomyopathy Risk in Multiple Myeloma Patients
Jha, A., Morgado, I., Lee, D. J., Alexander, K., Tsai, C.-Y., Schimmel, K., … Dangwal, S. (2019). Gene Signatures to Distinguish Amyloid Cardiomyopathy Risk in Multiple Myeloma Patients. CIRCULATION RESEARCH, 125. -
Single-cell mutational profiling enhances the clinical evaluation of AML MRD.
Ediriwickrema, A., Aleshin, A., Reiter, J. G., Corces, M. R., Köhnke, T., Stafford, M., … Majeti, R. (2020). Single-cell mutational profiling enhances the clinical evaluation of AML MRD. Blood Advances, 4(5), 943–52. -
Clinical Outcome with Allogeneic Hematopoietic Stem Cell Transplantation after Blinatumomab or Inotuzumab Ozogamicin in Patients with B-Cell Acute Lymphoblastic Leukemia: Real World Experience
Badar, T., Advani, A. S., Liedtke, M., Arslan, S., Khan, M. A., Aldoss, I., … Atallah, E. (2020). Clinical Outcome with Allogeneic Hematopoietic Stem Cell Transplantation after Blinatumomab or Inotuzumab Ozogamicin in Patients with B-Cell Acute Lymphoblastic Leukemia: Real World Experience. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. ELSEVIER SCIENCE INC. -
Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab Ozogamicin.
Badar, T., Szabo, A., Wadleigh, M., Liedtke, M., Arslan, S., Siebenaller, C., … Atallah, E. (2020). Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab Ozogamicin. Clinical Lymphoma, Myeloma & Leukemia. -
Outcomes in Patients With Cardiac Amyloidosis Undergoing Heart Transplantation.
Barrett, C. D., Alexander, K. M., Zhao, H., Haddad, F., Cheng, P., Liao, R., … Witteles, R. M. (2020). Outcomes in Patients With Cardiac Amyloidosis Undergoing Heart Transplantation. JACC. Heart Failure. -
Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab.
Badar, T., Szabo, A., Advani, A., Wadleigh, M., Arslan, S., Khan, M. A., … Atallah, E. (2020). Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab. Blood Advances, 4(10), 2308–16. -
Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma.
Lemieux, C., Muffly, L. S., Rezvani, A., Lowsky, R., Iberri, D. J., Craig, J. K., … Sidana, S. (2020). Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma. Bone Marrow Transplantation. -
Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden.
DeAngelo, D. J., Advani, A. S., Marks, D. I., Stelljes, M., Liedtke, M., Stock, W., … O'Brien, S. (2020). Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden. Blood Cancer Journal, 10(8), 81. -
Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone versus standard of care in MAMMOTH.
Cornell, R., Hari, P., Tang, S., Biran, N., Callander, N., Chari, A., … Costa, L. (2020). Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone versus standard of care in MAMMOTH. American Journal of Hematology. -
Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia.
Stock, W., Martinelli, G., Stelljes, M., DeAngelo, D. J., Gokbuget, N., Advani, A. S., … Kantarjian, H. M. (2020). Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia. Cancer. -
Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia.
Badar, T., Szabo, A., Dinner, S., Liedtke, M., Burkart, M., Shallis, R. M., … Atallah, E. (2020). Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia. Cancer. -
Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology.
Kumar, S. K., Callander, N. S., Adekola, K., Anderson, L., Baljevic, M., Campagnaro, E., … Kumar, R. (2020). Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN, 18(12), 1685–1717. -
Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis.
Premkumar, V. J., Lentzsch, S., Pan, S., Bhutani, D., Richter, J., Jagannath, S., … Kapoor, P. (2021). Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis. Blood Cancer Journal, 11(1), 10. -
Routine use of gemtuzumab ozogamicin in 7?+?3-based inductions for all 'non-adverse' risk AML.
Ladha, A., Hui, G., Cheung, E., Berube, C., Coutre, S. E., Gotlib, J., … Mannis, G. N. (2021). Routine use of gemtuzumab ozogamicin in 7?+?3-based inductions for all 'non-adverse' risk AML. Leukemia & Lymphoma, 1–6. -
Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia.
Advani, A. S., Larsen, E., Laumann, K., Luger, S. M., Liedtke, M., Devidas, M., … Stock, W. (2021). Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia. Blood Advances, 5(2), 504–12. -
AL Amyloidosis for the Cardiologist and Oncologist Epidemiology, Diagnosis, and Management
Witteles, R. M., & Liedtke, M. (2019). AL Amyloidosis for the Cardiologist and Oncologist Epidemiology, Diagnosis, and Management. JACC: CARDIOONCOLOGY, 1(1), 117–30. -
Autologous stem cell transplantation versus no transplant in patients above 70 with multiple myeloma.
Lemieux, C., Muffly, L. S., Iberri, D. J., Rezvani, A., Lowsky, R., Frank, M. J., … Sidana, S. (2020). Autologous stem cell transplantation versus no transplant in patients above 70 with multiple myeloma. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Impact of proteasome inhibitor vs. IMiD maintenance therapy on outcomes of patients with high-risk multiple myeloma (HRMM).
Tam, E. L., Iberri, D. J., Liedtke, M., Muffly, L. S., Shiraz, P., Frank, M. J., … Sidana, S. (2020). Impact of proteasome inhibitor vs. IMiD maintenance therapy on outcomes of patients with high-risk multiple myeloma (HRMM). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Avoiding Catastrophe: Understanding Free Light Chain Testing in the Evaluation of ATTR Amyloidosis.
Witteles, R. M., & Liedtke, M. (2021). Avoiding Catastrophe: Understanding Free Light Chain Testing in the Evaluation of ATTR Amyloidosis. Circulation. Heart Failure, CIRCHEARTFAILURE120008225. -
Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data.
Badar, T., Szabo, A., Litzow, M., Burkart, M., Yurkiewicz, I., Dinner, S., … Atallah, E. (2021). Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data. Bone Marrow Transplantation. -
Antibody-based therapies in patients with acute lymphoblastic leukemia
Dinner, S., & Liedtke, M. (2018). Antibody-based therapies in patients with acute lymphoblastic leukemia. HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 9–15. -
Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma.
Lemieux, C., Muffly, L. S., Iberri, D. J., Craig, J. K., Johnston, L. J., Lowsky, R., … Sidana, S. (2021). Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma. Bone Marrow Transplantation. -
Structural changes of corneal epithelium in belantamab-associated superficial keratopathy using anterior segment optical coherence tomography.
Matsumiya, W., Karaca, I., Ghoraba, H., Akhavanrezayat, A., Mobasserian, A., Hassan, M., … Nguyen, Q. D. (2021). Structural changes of corneal epithelium in belantamab-associated superficial keratopathy using anterior segment optical coherence tomography. American Journal of Ophthalmology Case Reports, 23, 101133. -
Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia.
Muffly, L., Sundaram, V., Chen, C., Yurkiewicz, I., Kuo, E., Burnash, S., … Miklos, D. B. (2021). Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia. Blood Advances, 5(16), 3147–3151. -
A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma.
Ramasamy, K., Nooka, A., Quach, H., Htut, M., Popat, R., Liedtke, M., … Cho, H. J. (2021). A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma. Blood Cancer Journal, 11(9), 149. -
Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALL.
Wieduwilt, M. J., Yin, J., Wetzler, M., Uy, G. L., Powell, B. L., Kolitz, J. E., … Larson, R. A. (2021). Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALL. Blood Advances. -
Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
Brown, P. A., Shah, B., Advani, A., Aoun, P., Boyer, M. W., Burke, P. W., … Campbell, M. (2021). Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN, 19(9), 1079–1109. -
A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma
Paul, B., Liedtke, M., Monge, J., Chaudhry, M., Rifkin, R., Gandhi, M., … Usmani, S. (2021). A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma. AMERICAN JOURNAL OF HEMATOLOGY. WILEY. -
Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies.
Bal, S., Malek, E., Kansagra, A., Usmani, S. Z., Vij, R., Godby, K. N., … Costa, L. J. (2021). Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies. Leukemia. -
Event free survival in adults with relapsed ALL who underwent front-line therapy with CALGB 10403.
Raychaudhuri, S., Yurkiewicz, I., Mannis, G. N., Medeiros, B. C., Coutre, S. E., Muffly, L. S., & Liedtke, M. (2021). Event free survival in adults with relapsed ALL who underwent front-line therapy with CALGB 10403. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Triple-class refractory disease as a modern therapeutic benchmark for clinical trials testing new agents for relapsed refractory Multiple Myeloma
Malek, E., Kansagra, A., Costa, L., Usmani, S. Z., Vij, R., Kumar, S., … Liedtke, M. (2021). Triple-class refractory disease as a modern therapeutic benchmark for clinical trials testing new agents for relapsed refractory Multiple Myeloma. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. CIG MEDIA GROUP, LP. -
Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma.
Costa, L. J., Lin, Y., Cornell, R. F., Martin, T., Chhabra, S., Usmani, S. Z., … Hari, P. (2021). Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma & Leukemia.
Clinical Trials
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
- A Safety Study of SEA-BCMA in Patients With Multiple Myeloma »
- Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia »
- Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma »
- Phase I/II Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma »
- A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis »
- A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia »
- A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis »
- Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis »
- The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis »
- The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis »
- Longterm Follow-up of Subjects Treated With bb2121 »
Practice Locations
Hematologic Cancer Program Palo Alto, CA
Palo Alto, CA
Hematologic Cancer Program
875 Blake Wilbur Drive
Palo Alto , CA 94304
Make An Appointment More Clinic Information » Getting Here »Amyloid Center Stanford, CA
Stanford, CA
Amyloid Center
300 Pasteur Drive , 2nd Floor, Room A260
Stanford , CA 94305
Make An Appointment More Clinic Information » Getting Here »Patient Reviews
(186 reviews)
Dr Liedtke is a lovely human being and a good doctor. However she is not clairevoyant and cannot guess what is happening to the patient's body without having physical contact.
Dr Liedtke is very patient and helpful in responding to my questions. I always feel like I am in very good hands and am genuinely cared for.
Excellent Doctor and appreciate her thorough care and listening to the issues and problems that I am currently dealing with.
very caring
She is terrific
She is very responsive to the patient's concerns.
I thought she was very thorough and very personable.
Wonderful doctor and person!
Very happy with the visit
Excellent, kind, supportive, passionate patient care!!
Michaela Liedtke is a very personable person with great expertise in her field. She can explain things clearly and thoughtfully. She is knowledgeable with future research that is being done with regards to my rare disease and shares it with me.
Dr. Liedtke is excellent, very blessed to have her on my team
I think she is a wonderful doctor in partnering with me in caring for my health. Her approach to my care is a perfect fit for me because she truly listens and offers her expertise which I value greatly.
She is a wonderful, knowledgeable doctor. I am so glad we were able to see her again. I know my health is in the best hands with Dr. Liedtke.
I had a very positive experience with Dr. Liedtke. She is professionally astute and personally engaging. I would definitely return to her if diagnosed with a hematological issue.
She's the best!
Dr. Liedtke is a very knowledgeable and compassionate doctor. I am lucky to have her as my hematologist.
I liked her personally and professionally and found her suggested road forward consistent with what I had read on pubmed.org
She is always wonderful and I very much like talking with her to update my health situation.
She is a world expert, very accessible, great supporting team and has an outstanding personal style.
She was very approachable and knowledgeable. I really appreciated her.
Dr. Liedtke is an excellent provider.
Great doctor, very satisfied with the information provided, cleared my doubts.
So we’ll informed and with an articulate way of sharing valuable information for me. I’m very grateful!
She is a wonderful, caring, and thorough doctor who I am very confident of
I am very lucky to have Dr. Liedtke as my physician. She is very thorough, smart and personable. I feel secure under her care.
She's the best.
Dr, Liedtke. Is a blessing in my continued treatment for Amyloidosis. My family and I are so grateful to Dr. Liedtke and her team for
their expertise and continued care.
Very patient and able to provide useful information about my treatment questions.
She is above fabulous…seriously!
Awesome! Thank you so much ;)
I can not think of anything further to say.
Dr. Liedtke is an outstanding physician. She hears her patients and her focus is on patient quality of life. That is unique in today's world of medicine.
Wonderful doctor explains very well the options in treatment that you have
Dr. M. Liedtke is an OUTSTANDING Physician to whom I entrust my life.
The Stanford Amyloid Center is an incredible success. Thank you.
Wonderful person and doctor. she and her team are keeping me going with a very high quality of life.
Excellent visit
Very please with her and information she provided.
Very thorough and very personable
She's very patient-friendly, extremely knowledgeable, and very informative.
I appreciated her thoroughness in explaining the treatment protocol and side effects.
Dr. Liedtke is extremely knowledgeable and conscientious. She cares about me and has been prompt in her replies and treatment.
I feel very fortunate that she is my hematologist.
The reason I marked very likely vs extremely likely re recommending Michaela was because the visit was so short (a good thing) that it didn’t allow getting to know her better. I was very satisfied with her care.
Dr Leidtke is the warmest most personable Dr I’ve ever met. Add to it her knowledge of myeloma and I cannot say enough praises for her care. She understands how hard this disease is and all the psychological factors with it. She makes me feel cared for, important and special. She wants to hear from me and she is so different than other Doctors I. The way she cares.
She is fantastic. Very knowledgeable, helpful and polite.
Very informative and friendly and kind which was most appreciated
She's always great. Thank you, Dr Liedtke! (And Thomas was good too.)
She is a great doctor, very thorough and communicates very well.
I did on the previous page.
Dr. Liedtke made me feel at ease. She explained everything to me and my son was able to take notes for me. It was nice of her to say my family can reach out to her if they have any questions or concerns. I enjoyed chatting with her.
Dr. Liedtke is a compassionate physician who provides the needed clarity to a complex health situation. Greatly appreciate her as she has made all the difference to my accepting my diagnosis- because I know she will be there alongside. Thank you, Dr. Liedtke.
Very knowledgeable and helpful as well as genuine ly concerned about my health situation.
She is great!
Excellent
Terrific Doctor and terrific video visit
I appreciated her concern about my case. Ditto for Dr. Gupta.
Dr. Liedtke is an excellent provider. She listens. She includes me in the decision making process for my care. She is an advocate for her patients.
However, it seems that physicians can be limited by what Stanford is able or willing to offer as options (i.e. specifically in regard to vaccine boosters for immunocompromised patients).
Great doc/ great person!
Please see previous answer. She is excellent in all aspects her superior, up to date knowledge, clinical acumen, her sensitivity, a healer. I am very grateful.
Dr Liedtke was concerned and took the time to make sure all my concerns were addressed.
Dr Liedke has a very approachable demeanor. She is very knowledgeable about the rare disease I have and shows concern as well as empathy knowing what I go through. She listens to what I have to say and evaluates according. I had very fond opinion of the care she give me.
I have been a patient of Dr Liedtke’s for many years. She is always thoughtful and thorough. I place my trust in her for my current and future treatments of Multiple. Myeloma.
Dr. Liedtke is smart, personable, and compassionate - a rare combination.
She is wonderful.
She is a wonderful doctor who I am extremely grateful for. She is extremely knowledgeable, caring and personable. I have full faith in her.
Dr Liedtke is amazing, I feel very fortunate to have her as my oncologist
Very knowledgeable and compassionate.
Very thorough.
Very caring
She seems to be a very nice and caring doctor. I felt very comfortable with her.
Dr. Liedtke is personable, friendly and listens to me. She really cares about her patients!
Very supportive, provided update on the chemo I am taking.
Very nice and excellent physician.
I think she was great. She answered all my questions and did not try to answer what she didn't know. Instead she promised to look that question up and get back to me. I appreciate that.
Dr Liedtke is always very responsive and supportive.
Dr Liedtke was very empathic, highly knowledgable, thorough and great at communicating the complex issues surrounding my condition.
Good visit
Thanks
Excellent
I really appreciate Dr. Liedtke"s attention to every detail related to my health condition. She has a very pleasant attitude and I feel comfortable to discuss any issues and symptoms I may have with her. Her extensive knowledge and research about my condition makes me confident I am in good care. Thank you Dr. Liedtke.
She is very knowledgeable and I feel hopeful and reassured talking to her. I am optimistic that I shall continue to receive excellent care through her and Stanford.
Dr. Leidtke is a very good in taking care of my illness.
She is one of the best doctors I’ve every dealt with and since my case is rare- I’ve seen many Drs! Cannot say enough about her calm compassionate demeanor- after many different and some alarming diagnosis- she seems to understand the complexities of my situation with her knowledge and made me have hope for the first time in awhile!!
Dr. Liedtke is an outstanding doctor. She is aware of your medical condition and gives advice accordingly to needs.
I would highly recommend her for help.
See prior comment. She is awesome!
She was very friendly and helpful
I really like her demeanor, enthusiasm and attitude towards my case and well-being. She will be in touch with my oncologist and is looking at doing the stem cell transplant treatment prior to my mastectomy; a different approach than what Kaiser had been considering for the last year. She is also surprised that I did not have a primary breast cancer oncologist assigned to me while working concurrent with the multiple myeloma/hematology oncologist. This makes sense to me although all the oncologist are part of the tumor board.
Dr. Liedtke is absolutely the best doctor and extremely knowledgeable. I needed a second opinion when the doctors at UCLA could not determine what was wrong with me. I did an internet search and found Stanford had the specialty department and the doctors I needed. I cannot say enough about Dr. Liedtke and she is a true hero in my book.
Allowed me to ask questions & answered completely.
Highly competent, compassionate, caring and is a very nice person. Dr. Liedtke is patient and explains things very clearly. If there was an issue I would have complete confidence that it would be properly handled. It is enjoyable to work with her. Just outstanding in every way from my perspective. I am grateful to be in her care. Wow!
I appreciate how Dr. Liedtke listens to all my concerns and takes the time to answer all my questions.
Dr. Liedtke is a superstar physician.
Love Dr. Liedtke!
Love Dr. Liedtke!!
Great to have Dr. Liedtke for my care.
Dr. Liedtke has always been excellent to work with in addition, the attending fellow was quite good as well.
Everyone is so kind & helpful.
Dr. Liedtke is magnificent!
Being with Dr. Liedtke was a wonderful experience! She is everything a good doctor should be.
Dr. Michaela was so outstanding and I really appreciate the time she gave me. She the rare few that didn't rush me like I was a number.
Very good.
I had a very positive experience with all care providers, felt taken care of and given information for my understanding.
Dr. Liedtke is amazing; The resident fellows have been amazing too. Very professional and knowledgeable.
Live in N. Nevada. Love Dr. Liedtke. I wish we could see her every month!
I have often referred her to new people in my surgery group.
All Stanford docs I've had the last 15 yrs. have been excellent!
Excellent.
Dr. Liedtke was great!
All good.
Dr. Liedtke is excellent, the MD doing the initial consult was quite good as well.
I seen Dr. Greg Kaufman first the Dr. Liedtke. Thy were both amazing, I felt very comfortable with both. Dr. Liedtke was very nice and she made me feel like she really cared about me & my situation.
Found Dr. Liedtke and her asst. more than caring, knowledgeable and compassionate. I was so honored to have a doctor of her repute to work with me. She gave me hope, I'll never forget her and my experience with her.
Excellent experience.
Very good.
I was thoroughly pleased with Dr. Liedtke's explanation, I feel so blessed that she is my care provider.
Explained everything and answered all our questions and concerns. Very patient and understanding. A very caring person.
Dr. Liedtke and her resident fellow, Greg Kaufmann were amazing - so put me at ease - this was my first visit to Stanford and I was very impressed with both doctors.
Outstanding! Very thorough.
Every staff member seems to exert the same respect & courtesy to my wife & while we are there.
Dr. Michaela Liedtke is a great asset to your hospital, also Dr. Ronald Witteles. THANK YOU.
Dr. Liedke is a great doctor. Shows concern compassion in clinic encounter each and every visit.
She is always awesome never rushes.
We LOVE Dr. Liedtke.
She is excellent!
Dr. M. Liedtke, like Dr. LaPorte and Goldstein before her all excellent. Also, she works well with my local physician - coordinating my care.
My visit was a very good one.
Listened well to my questions/concerns. Explained thoroughly.
God bless you always I have had a very good experience on being treated by you.
Always very good.
They met all my expectations.
Reassurance on care needed given.
I was so impressed with Dr. Liedtke, her fellow, and everything else about Stanford that I've decided to use Stanford instead of UCSF.
She has taken the time to call me at home with suggestions on my care.
The best ever!!
Empathy very evident... reassuring experience.
I feel I have received outstanding care form Dr. Liedtke.
Good.
Good.
Excellent care and concern shown by Dr. Liedtke and Misty Mahaffey (NP) at my clinic appointment.
Dr. Liedtke is a very kind, caring, and a great doctor!
Love my oncologist, palliative. They are so kind.
All good.
They had me... with my questions that they were doing thanks.
All very good.
I have been very happy with the care I have received from Dr. Liedtke.
All very nice.
She is very respectful of my opinion. She is a very humble person, which is unusual in a MD.
Excellent svc.!
Dr. Liedtke is a fantastic doctor. The best I've ever seen. She explain everything to me and my family. It shows that she really cares -
Dr. Liedtke is the best - caring, informative and knowledgeable. I would recommend her to everybody.
Dr. Liedtke is genuinely caring - and competent - a combination that is exceptional.
She took the time to provide a detailed and clear explanation regarding my condition, the possibilities and her plan of action. Dr. Liedtke was EXCELLENT I have high confidence in this doctor.
Love Dr. Liedtke.
Dr. Liedtke is the best. She explains and shows concern for my health. I have complete confidence in her.
All very good.
Dr. Liedtke is wonderful - feel very fantastic to have her as my specialist.
We really love Dr. Liedtke. She is so caring and knowledgeable. We are lucky to have her as a provider. It is hard to find a doctor like her.
Outstanding physician for my particular disease.
Dr. Liedtke is a great communicator and inspires my confidence in her. I have a lot of questions and she listens and answers them all she is fully responsive to email communications and volunteered her work e-mail address.
Dr. Liedtke, PA, and NP were very knowledgeable. I could ask for any more professional staff to assist me.
I feel so fortunate to have Michaela Liedtke as my myeloma specialist. She answered questions, listens, is informative and caring - truly top notch - could not be in better hands.
Excellent doctor always concerned for me.
My experience with the nurses & doctors was great.
Good.
I feel very fortunate and grateful to be cared for by Dr Liedtke
Nice and very kind.
I have the utmost confidence in Dr. Liedtke.
Love everyone at Stanford they are kind and careing and very smart! I would not be alive if I didn't have Stanford to go to that's why I drive four hours to get there!
Dr Liedtke has been my doctor for eight years. She is very helpful, understanding, knowledgeable about my disease. My pain, my feelings and knows what treatment I need. She is the same the first time I saw her and until now. I am confident that she can cure me.
Excellent! Dr Liedtke is a great communicator. She always understands exactly what I'm asking and gives precise, understandable answers. She has never appeared rushed with me, giving all the time I need to ask questions. She is also very kind.
She was an awesome doctor. I was lucky and blessed to have her. She was so kind and considerate. A confident and gentle spirit and a great leader for her staff.
I have the highest degree of admiration and respect for Dr. Liedtke.
Dr. Liedtke is the best doctor I have ever had. I have seen many, but she by far is the very best. I am very blessed to have her.
Dr. Liedtke is very good at responding to messages with questions or concerns I might have between regular appointments. This is all done electronically through the website with no need for phone calls.
Fantastic.
Thank you Dr Liedtke
Always a good experience Dr. Liedtke is very caring and concerned; she always explains my condition in a way I understand. I really like Dr. Liedtke. She's a sweetheart!!!
Very pleased with my doctor - Excellent care - Dr. Liedtke.
Have been very impressed with Dr. Liedtke in all my dealings with her.
Dr. Liedtka listens to you and ask questions. She is understanding of your needs. Being a scrub nurse, I do not do things normally in my medical history. She understands that. She is great.
Impressive MD's!
No bad experience.
Dr. Liedtke is saving my life!
Dr. Liedtke had not seen us before, so she was a little surprised, but did a great job.
She's a sweetheart - We're very blessed to be in her care.
I am very confident with Dr. M Liedtke. Her name is outstanding.
Dr. Liedtke is excellent.
Good.
View More »
Referring Physicians
PHYSICIAN HELPLINE
Phone: 1-866-742-4811
Fax: 650-320-9443
Monday – Friday, 8 a.m. – 5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referring Physicians.
- Send referrals online
- View referral status
- Access medical records